PlateletBio announces $75.5M Series B to extend autoimmune cell therapy

Josh Sullivan

More than two years after PlateletBio landed its first round of fundraising and a contract with the US government, the company announced its Series B …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PlateletBio announces $75.5M Series B to extend autoimmune cell therapy

Josh Sullivan

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Eikon Therapeutics raises $351M Series D as lead drug starts Phase 3

AstraZeneca’s SERD hits primary endpoint in late-stage trial, but first-line potential remains uncertain

CBER's deputy director departs as staff shakeup continues

Ginkgo uncertain over the future of US government funding, stock drops

Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugs

How AI can address ongoing challenges in the life sciences industry

Platelet­Bio an­nounces $75.5M Se­ries B to ex­tend au­toim­mune cell ther­a­py

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

PlateletBio announces $75.5M Series B to extend autoimmune cell therapy